CITI/PUT/MODERNA/80/0.1/19.09.24 | Market Closed - Deutsche Boerse AG 18:32:53 31/05/2024 BST | ||
| 0.032 EUR | +100.00% |
|
| 1 month | -87.20% | ||
| 3 months | -95.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.032 | +100.00% |
| 30/05/24 | 0.016 | -40.74% |
| 29/05/24 | 0.027 | -.--% |
| 28/05/24 | 0.027 | +237.50% |
| 27/05/24 | 0.008 | +14.29% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 06:32 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Citi
|
| WKN | KH768K |
| ISIN | DE000KH768K1 |
| Date issued | 19/07/2023 |
| Strike | 80 $ |
| Maturity | 19/09/2024 (109 Days) |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.04 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
142.6
USD
Average target price
139.9
USD
Spread / Average Target
-1.83%
- Stock Market
- Warrants
- Warrant
